Congratulations to the Biorce team on securing €5 million to scale AI in clinical trials!
The Barcelona-based startup is transforming how trials are designed and executed with Jarvis — their AI-native platform trained on over 500,000 studies. This round, led by Norrsken VC, will help them expand into new markets and empower pharma teams to plan smarter, faster trials. Special kudos to CEO Pedro Coelho for turning a personal story into a mission that’s now reshaping drug development across Europe. This is a big win not just for Spain, but for practical, real-world AI in biotech
Barcelona-based healthtech company Biorce has raised €5 million in a new investment round to accelerate the development and international expansion of its AI-powered clinical trial platform. The funding, led by Swedish impact investor Norrsken VC, marks a significant milestone for one of southern Europe’s most promising digital health startups.
Founded in Spain in 2021, Biorce has developed an AI-native platform called Jarvis, designed to optimise how clinical trials are planned, designed and executed. Drawing on real-world data from over 500,000 previous studies, the system helps pharmaceutical companies, contract research organisations and biotechs make more informed decisions across the entire clinical development process—from protocol design and site selection to patient recruitment and trial feasibility.
Delays and protocol amendments are a known weakness in clinical research. Across Europe and globally, trials frequently run over time and budget, with many encountering costly mid-study design changes. These issues not only waste resources but delay patients’ access to new therapies. Biorce aims to address this with its AI tool that delivers predictive insights and scenario planning early in the design phase, potentially cutting weeks or months from the development timeline.
Pedro Coelho, co-founder and CEO of Biorce, said the inspiration for the company came from his own family’s experience with cancer treatment. His father’s participation in a clinical trial extended his life, highlighting both the life-saving potential and the inefficiencies within the system. Coelho said Biorce’s mission is to ensure more patients across Europe and beyond can benefit from faster, more efficient trial access.
The €5 million in fresh capital will be used to expand Biorce’s engineering and commercial teams, improve its platform architecture, and scale operations into new markets, particularly within the EU and United Kingdom. The company currently operates across Spain, the UK and the Nordic region, and is preparing for further expansion into central and eastern Europe. The startup had previously raised €3.5 million in a seed round led by YZR Capital and Mustard Seed Maze in late 2024, bringing its total raised to €8.5 million.
Norrsken VC, known for backing purpose-driven European technology companies, described Biorce as a standout case of mission and business impact aligning. General Partner Tove Larsson said the company is solving a critical bottleneck in drug development and could be instrumental in helping patients access treatments sooner across the continent.
Biorce’s platform is already being used by clients conducting trials in oncology, neurology and immunology. In addition to enhancing planning and execution, the AI software helps sponsors meet increasingly stringent regulatory expectations around trial design transparency and data quality—issues of growing importance within the European Medicines Agency and national regulators.
Industry data shows that Europe remains a leading global region for clinical research, but competition is increasing. Countries like Germany, France, Spain and the Netherlands are investing heavily in decentralised trials, patient-centric design and digital tools. Biorce’s approach, which combines data analytics with regulatory and operational context, is positioned to support that shift and complement Europe’s drive for innovation in health.
As the European clinical trial landscape evolves to embrace AI and evidence-based design tools, Biorce hopes to play a central role in shaping more efficient, ethical and accessible research frameworks. With this new funding round secured and growing interest from trial sponsors, the company is poised to help modernise how therapies are brought from the lab to the clinic—not just in Spain, but across the wider European life sciences ecosystem.